Hedlund H, Andersson K E
Department of Urology, Lund University Hospital, Sweden.
Scand J Urol Nephrol. 1988;22(1):19-22. doi: 10.1080/00365599.1988.11690378.
To eight patients with benign prostatic obstruction (BPO), prazosin and placebo were given in a double blind cross-over manner. Prazosin decreased significantly residual urine volume and increased maximum and average flow rates. Neither when treated with prazosin nor with placebo, did the patients improve their ability to empty the bladder after injection of carbachol (0.25 mg) s.c. The only significant effect of carbachol on urodynamic variables was an increase in intravesical premicturition pressure. This was observed both when the patients were treated with prazosin and with placebo. Fourteen patients with BPO were given oral carbachol in maximally tolerated doses (6 or 12 mg/day) during a 2 week period. Despite producing significant systemic side effects in all patients, carbachol did not change any of the urodynamic variables tested. It is concluded that carbachol does not further improve bladder emptying in BPO patients given prazosin. Oral carbachol has no effects on bladder emptying in these patients.
对8例良性前列腺梗阻（BPO）患者，以双盲交叉方式给予哌唑嗪和安慰剂。哌唑嗪显著减少残余尿量，增加最大尿流率和平均尿流率。无论是用哌唑嗪还是安慰剂治疗，患者在皮下注射卡巴胆碱（0.25mg）后膀胱排空能力均未改善。卡巴胆碱对尿动力学变量的唯一显著影响是膀胱内排尿前压力升高。在患者接受哌唑嗪和安慰剂治疗时均观察到这一点。14例BPO患者在2周内给予最大耐受剂量（6或12mg/天）的口服卡巴胆碱。尽管在所有患者中均产生显著的全身副作用，但卡巴胆碱并未改变任何测试的尿动力学变量。结论是，在给予哌唑嗪的BPO患者中，卡巴胆碱不能进一步改善膀胱排空。口服卡巴胆碱对这些患者的膀胱排空无影响。
